With the coronavirus pandemic spreading to nearly every country in the world, the number of hospital patients needing respiratory support is becoming unprecedented. It’s not easy for manufacturers to ...
Needham analyst Mike Matson reiterated a Buy rating on ResMed Inc. (NYSE:RMD) with a price target of $180. ResMed registered a street-beating performance in the first quarter, where revenue increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback